AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Creutzfeldt-Jakob Disease

Recent research efforts aimed at curing Creutzfeldt-Jakob Disease.

Last updated

Creutzfeldt-Jakob Disease

Overview

Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive, fatal brain disorder caused by a prion: a normally occurring protein that misfolds and induces other prion proteins to misfold. The resulting buildup damages brain cells and causes rapidly worsening dementia, problems with coordination and movement, involuntary jerks, visual symptoms, and eventually severe loss of function. Most classic CJD is sporadic, meaning it occurs without a known cause; rarer forms are inherited through disease-causing variants in the PRNP gene or acquired through medical exposure or, in variant CJD, exposure to bovine spongiform encephalopathy. It usually affects older adults, and death commonly occurs within months to a year after symptoms start. CDC overview of classic CJD

There is currently no approved treatment that slows, stops, or reverses CJD. Standard care is therefore supportive and palliative: managing distressing symptoms, preventing complications, assisting families with care decisions, and providing hospice support when appropriate. CDC overview of classic CJD

Scope of Recent Research (2020–present)

Research since 2020 has become more focused and biologically targeted: rather than mainly testing repurposed drugs, leading programs aim to reduce production of normal prion protein (PrP), the essential raw material that prions convert into their harmful form. The field is small because CJD is rare and progresses quickly, but it has advanced from animal proof-of-concept studies to several first-in-human RNA-lowering trials. These are important milestones, but no approach has yet demonstrated clinical benefit in people, so a curative therapy is not yet close. Therapeutic strategies in prion disease

Major Breakthroughs and Emerging Therapies

The strongest therapeutic rationale is PrP lowering. Antisense oligonucleotides (ASOs) are short, chemically modified strands of nucleic acid that bind an RNA message and cause it to be degraded, thereby reducing production of a chosen protein. In 2020, researchers showed that ASOs targeting mouse Prnp RNA prolonged survival across multiple prion strains and disease stages; chronic treatment begun before major neurological damage was most effective, while treatment after clear symptoms produced benefit only in a subset of mice. Prion protein lowering across disease stages This work directly supported development of the human PrP-lowering ASO ION717.

A second RNA-lowering platform is divalent small interfering RNA (siRNA). siRNA works through RNA interference, a natural cellular process that cuts a targeted RNA message. In a 2026 preclinical study, a divalent siRNA against mouse Prnp reduced brain PrP and increased survival 2.7-fold when repeatedly administered before symptoms; a single dose after symptom onset increased survival by 64% in infected mice. The investigators also developed human-PRNP mouse models and identified a human-targeting candidate that substantially lowered PrP in brain tissue, enabling entry into clinical testing. Divalent siRNA for prion disease

Permanent or long-lasting gene regulation is another emerging strategy. A 2024 study reported CHARM, a compact epigenetic editor delivered by adeno-associated virus (AAV) that uses engineered zinc-finger proteins to silence the Prnp gene without cutting DNA. In mice, one brain-directed AAV treatment reduced PrP by up to 80% after six weeks; the editor was also designed to switch itself off after accomplishing gene silencing. This is an early animal-stage approach, not a human therapy, but it could eventually offer a one-time alternative to repeated spinal injections. Brainwide prion-protein silencing by CHARM

Immunotherapy has provided a separate proof that PrP can be reached in the human brain. In a 2022 report, the MRC Prion Unit at University College London treated six people with probable CJD using PRN100, an intravenous humanized monoclonal antibody that binds normal PrP. Repeated dosing was generally tolerated and achieved target drug levels in cerebrospinal fluid in four participants, but every participant continued to decline neurologically; the small, uncontrolled program could not establish efficacy. First-in-human PRN100 treatment programme Small-molecule discovery remains active, but it has been difficult to find compounds that bind PrP strongly enough to become credible medicines; a large 2020 screen found only a very weak candidate binder. Multimodal small-molecule screening for PrP binders

Clinical Trials and Experimental Approaches

The most advanced PrP-lowering program is PrProfile (NCT06153966), a Phase 1/2a trial of intrathecal ION717 sponsored by Ionis Pharmaceuticals. ION717 is an ASO intended to lower PrP production in the central nervous system. The trial evaluates safety, tolerability, drug exposure, and pharmacodynamic effects—whether the medicine lowers its intended target—rather than being designed to prove a cure. As of October 10, 2026, the Canadian trial record listed the study as active but not recruiting. PrProfile trial record Enrollment of the original symptomatic cohort was completed in December 2024, with participants able to enter a 70-week open-label extension; public efficacy results have not been reported. Ionis December 2024 community statement

The PRiSM trial (NCT07444580) is a first-in-human Phase 1 study of intrathecal PrP-siRNA developed by the Broad Institute and UMass Chan Medical School. It began enrolling symptomatic patients in 2026 and is designed primarily to test safety, dose levels, drug levels, and reduction of PrP in cerebrospinal fluid. The study is supported through the NIH NeuroNEXT network and includes an observational comparison group. PRiSM trial announcement The program is especially notable because its preclinical data and regulatory-development process have been publicly described, but it remains far too early to know whether it will alter patients’ outcomes. Divalent siRNA for prion disease

A third PrP-targeting program, ALN-6457 (ALN-PRNP; NCT07832370), was listed in September 2026 as a Regeneron-sponsored Phase 1/2 open-label study of multiple doses in adults with symptomatic prion disease. The planned trial will assess safety, pharmacokinetics, target effects, and exploratory efficacy, but its registry status was not yet recruiting as of September 26, 2026; therefore, no outcomes are available. ALN-6457 trial record

Methodologies and Scientific Approaches

Researchers combine infected mouse models, genetically engineered mice carrying human PRNP, cultured cells, and human stem-cell-derived brain organoids to test whether an intervention reduces prion replication, prevents neuronal injury, and improves survival. Human cerebral organoids—three-dimensional, stem-cell-derived mini-tissues that model aspects of the brain—can propagate human CJD prions and have been used to test candidate drugs in a human genetic setting. Human cerebral organoids for CJD drug screening These models are useful but imperfect: they cannot fully reproduce the long, complex biology of human CJD or reliably predict benefit after patients have developed extensive brain injury.

Trial development also depends on biomarkers. Researchers use MRI, cerebrospinal-fluid tests, and real-time quaking-induced conversion (RT-QuIC), an assay that amplifies and detects prion-seeding activity, to improve diagnosis and to monitor disease. Cerebrospinal-fluid PrP is particularly important for PrP-lowering drugs because it can serve as a pharmacodynamic marker of whether a treatment is engaging its target; neurofilament light chain and tau may help track neuronal damage and stratify participants. CSF biomarkers for prion diseases Biomarkers in people at genetic risk

Leading Institutions and Funding

The Broad Institute of MIT and Harvard, UMass Chan Medical School, Massachusetts General Hospital, and the NIH NeuroNEXT network are central to the PrP-siRNA program and the PRiSM trial. Ionis Pharmaceuticals leads the ION717 ASO program, while the MRC Prion Unit at University College London and UCL Hospitals developed and evaluated PRN100. The National Prion Disease Pathology Surveillance Center at Case Western Reserve University is also a major U.S. clinical and diagnostic hub supporting prion-disease studies. PRiSM trial announcement First-in-human PRN100 treatment programme

Public and philanthropic support remains essential because the disease is ultra-rare and trials are difficult to finance. NIH support for recent PrP-silencing work has included NINDS, the Somatic Cell Genome Editing Program, NHGRI, NIBIB, the Department of Defense, Schmidt Sciences, and the Howard Hughes Medical Institute. NIH report on CHARM prion-protein silencing The CJD Foundation reports awarding more than $6 million through over 85 research grants and currently offers one-year awards up to $50,000 and two-year awards up to $100,000. CJD Foundation researcher grants

Strengths, Limitations, and Challenges

The field’s greatest strength is that PrP lowering is supported by a clear causal logic: normal PrP is required for prion propagation, and reducing it has repeatedly delayed disease or extended survival in animals. RNA medicines offer measurable target engagement in cerebrospinal fluid and can be redesigned if needed. The existence of three human PrP-lowering programs—ION717, PrP-siRNA, and ALN-6457—means that different molecular platforms are now testing the same core hypothesis. Prion protein lowering across disease stages PrProfile trial record ALN-6457 trial record

The central limitations are timing and uncertainty. CJD is often diagnosed only after substantial, irreversible brain injury, while the animal evidence suggests treatment is most powerful before or early in disease. Small patient numbers, diverse prion strains and genetic subtypes, very rapid decline, invasive spinal delivery, and the lack of validated clinical surrogate endpoints complicate trials. PRN100 also illustrates the distinction between target engagement and proven clinical benefit: drug reached the brain and appeared tolerable, yet disease progression was not halted or reversed in the six treated patients. First-in-human PRN100 treatment programme

Outlook and Future Directions

As of October 14, 2026, CJD has no cure, but the field has reached a consequential transition: multiple PrP-lowering therapies are now in or entering human trials. The most important milestones to watch are whether ION717, PRiSM, and ALN-6457 can safely and substantially lower PrP in cerebrospinal fluid; whether that target reduction changes biomarker trajectories or clinical decline; and whether prevention trials can be designed for people with high-risk PRNP variants before symptoms arise. A realistic near-term goal is not reversal of advanced CJD, but demonstrating that early PrP lowering can slow, halt, or delay disease—evidence that would establish the first credible path toward prevention and, ultimately, a functional cure. Biomarkers in people at genetic risk Therapeutic strategies in prion disease

References

Don't see your disease? Request a report